Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0L5XG
|
|||
Former ID |
DIB015388
|
|||
Drug Name |
PF-4191834
|
|||
Synonyms |
PF-04191834
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 2 | [1] | |
Company |
Pfizer Inc
|
|||
Structure |
Download2D MOL |
|||
Formula |
C22H23N3O2S
|
|||
Canonical SMILES |
CN1C(=CC=N1)C2=CC=C(C=C2)SC3=CC=CC(=C3)C4(CCOCC4)C(=O)N
|
|||
InChI |
1S/C22H23N3O2S/c1-25-20(9-12-24-25)16-5-7-18(8-6-16)28-19-4-2-3-17(15-19)22(21(23)26)10-13-27-14-11-22/h2-9,12,15H,10-11,13-14H2,1H3,(H2,23,26)
|
|||
InChIKey |
DVNQWYLVSNPCJZ-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 1029317-21-2
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Arachidonate 5-lipoxygenase (5-LOX) | Target Info | Inhibitor | [2] |
BioCyc | Aspirin-triggered lipoxin biosynthesis | |||
Resolvin D biosynthesis | ||||
Leukotriene biosynthesis | ||||
Lipoxin biosynthesis | ||||
Aspirin triggered resolvin D biosynthesis | ||||
Aspirin triggered resolvin E biosynthesis | ||||
KEGG Pathway | Arachidonic acid metabolism | |||
Metabolic pathways | ||||
Serotonergic synapse | ||||
Ovarian steroidogenesis | ||||
Toxoplasmosis | ||||
NetPath Pathway | IL4 Signaling Pathway | |||
Pathwhiz Pathway | Arachidonic Acid Metabolism | |||
WikiPathways | Vitamin D Receptor Pathway | |||
Arachidonic acid metabolism | ||||
Eicosanoid Synthesis | ||||
Selenium Micronutrient Network |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01147458) A Study Of The Safety And Efficacy Of PF-04191834 In Patients With Osteoarthritis Of The Knee. U.S. National Institutes of Health. | |||
REF 2 | Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain. J Pharmacol Exp Ther. 2010 Jul;334(1):294-301. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.